  Phenylephrine Hydrochloride (Neosynephrine) section { margin-bottom: 20px; } table { border-collapse: collapse; } table, tr, th, td { border: 1px solid black; } th, td { padding: 0px 8px 0px 8px; text-align: left; vertical-align: top; } h3, p, ol.custom-counter, li { margin: 0px; padding: 0px; } .text-red { color: red; } .text-black { color: black; } ul.custom-dash { list-style: none; padding-left: 0; margin: 0; } ul.custom-dash > li { display: flex; align-items: flex-start; } ul.custom-dash > li::before { content: "–"; margin-right: 0.5em; flex-shrink: 0; line-height: 1; } ul.custom-dash > li > \*:not(::before) { flex: 1; } ul.custom-dash > li.no-dash::before { content: ""; width: 1em; margin-right: 0.5em; flex-shrink: 0; } /\* Change the ol style \*/ ol.custom-counter { list-style: none; padding-left: 0; counter-reset: custom calc(var(--start, 1) - 1); } ol.custom-counter li { counter-increment: custom; margin-bottom: 5px; } ol.custom-counter li::before { content: counter(custom) ") "; } /\* This is just for this file \*/ ul.custom-bullet-arrow { list-style: none; padding-left: 0; margin: 0; } ul.custom-bullet-arrow > li { display: flex; align-items: flex-start; } ul.custom-bullet-arrow > li::before { content: "↑"; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet-arrow > li.no-arrow::before { content: ""; width: 0.5em; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet\_arrow ul { list-style-type: disc; padding-left: 1.5em; margin-top: 0.5em; } img.resized-200 { width: 200px; height: auto; } img.resized-400 { width: 400px; height: auto; } img.resized-600 { width: 600px; height: auto; } .mb-10px { margin-bottom: 10px; } .mb-20px { margin-bottom: 20px; } .mt-10px { margin-top: 10px; } .mt-20px { margin-top: 20px; } .reference-notes { font-size: 11px; } .text-indent-45px { text-indent: 45px; } .text-bold { font-weight: bold; } .text-italic { font-style: italic; } .text-center { text-align: center; }

### Phenylephrine Hydrochloride (Neosynephrine)

<table><tbody><tr><th style="width: 160px;">Class</th><td style="width: 450px;"><p>Alpha-1 adrenergic agonists.</p></td></tr><tr><th>Therapeutic class</th><td><p>Vasopressor</p><p>Decongestant: For colds or allergies</p></td></tr><tr><th>Indications</th><td><p class="text-bold">Anesthesia related indications (with normal EF):</p><p>Intraoperative hypotension with a normal to high heart rate.</p><p>Anesthesia-induced hypotension from the vasodilatory effects of propofol and/or inhalation agents.</p><p><b>Spinal-induced hypotension</b> in OB/GYN patients.</p><p><b>Aortic stenosis-</b> ↑ afterload</p><p class="mb-20px"><b>CAD patients:</b> Useful because it ↑coronary blood flow w/o chronotropic (↑ HR) side effects.</p><p class="text-bold">Other:</p><p><b>Spray:</b> Intra-nasally for constriction with nosebleeds and nasal intubations</p><p>Nasal decongestant</p><p>Ophthalmic formulations to facilitate mydriasis,</p><p>vasoconstriction of conjunctival blood vessels.</p><p><b>Urology:</b> Intracavernosal injections to treat acute ischemic priapism</p></td></tr><tr><th>Quick notes</th><td><p>Synthetic noncatecholamine</p><p class="mb-20px">Avoid with bradycardia because phenylephrine will ↓ HR via baroreceptor-mediated reflex (vagal) in response to ↑ diastolic pressure and stretch receptor neurons.</p><p><span class="text-red">Patients with ↓ EF: Avoid Phenylephrine.</span> A low dose inotrope like ephedrine or norepinephrine to treat temporary intraoperative hypotension is more optimal.</p><p>↓ Renal, splanchnic, and cutaneous blood flow</p><p>Use Sub Q phentolamine to treat tissue extravasation</p></td></tr><tr><th>IV mix</th><td><p>10 mg (one 1mL vial) in 250 mL bag of NS yields 40 mcg/mL <span class="text-red">(standard)</span></p><p>20 mg (two 1mL vials) in 250 mL bag of NS yields 80 mcg/mL</p><p>40 mg (four 1 mL vials) in 250 mL bag of NS yields 160 mcg/mL</p><p>5 mg (1/2 of one 1 mL vial) in 100 mLs bag of NS yields 50 mcg/mL</p><p>10 mg (one 1mL vial) in 100 mL bag of NS yields 100 mcg/mL</p><p>10 mg ((one 1mL vial) in 500 mL bag of NS yields 20 mcg/mL</p></td></tr><tr><th>Action</th><td><p>Directly stimulates alpha 1 adrenergic receptors</p><p>Primarily a vasoconstrictor with less arterial constriction (literature varies)</p><p>A small amount stimulates Alpha 2 receptors -little effect</p></td></tr><tr><th>Coronary blood flow</th><td><p class="text-red">↑ coronary perfusion w/o ↑ HR</p><p>It may ↓ myocardial blood flow or worsen angina in CAD patients.</p><p>Coronary vasospasms have been reported (with high doses and multiple pressors).</p></td></tr><tr><th>Dosing:</th><td><p>20-100 mcg boluses as needed</p><p>40 mcg or 80 mcg doses are the most common.</p><p class="text-bold">Infusion:</p><p>0.1-2 mcg/kg/min</p><p>0.5 mcg/kg/min is a common start</p><p>40-80 mcg/min</p></td></tr><tr><th>Clinical Duration</th><td><p>15-30 minutes</p></td></tr><tr><th>Onset</th><td><p>Rapid</p></td></tr><tr><th>Peak effect</th><td><p>42 seconds</p></td></tr><tr><th>Clinical Duration</th><td><p>10-15 minutes</p></td></tr><tr><th>Compatible diluents</th><td><p>Sodium chloride 0.9% or DW5</p></td></tr><tr><th>Side effects</th><td><p>Nausea, vomiting, headache, and nervousness in patients while awake.</p><p>Baroreceptor-mediated reflex bradycardia.</p></td></tr><tr><th>½ life of pressor action</th><td><p>5 minutes</p></td></tr><tr><th><p>Elimination ½ life</p></th><td><p>2.5 hours</p></td></tr><tr><th>Metabolism via IV</th><td><p>Hepatic by monoamine oxidase A and B, and SULT1A3.</p></td></tr><tr><th>Metabolites</th><td><p>m-Hydroxymandelic acid (3-HMA)</p><p>Phenylephrine-3-O-sulfate</p><p>Phenylephrine-3-O-glucuronid</p></td></tr><tr><th>Route of elimination</th><td><p>86% of a dose in the urine, with 16% as the unmetabolized drug,</p><p>57% as the inactive meta-hydroxymendelic acid</p><p>8% as inactive sulfate conjugates.</p></td></tr><tr><th>Pregnancy category</th><td><p>C</p><p>It does not appear to decrease placental perfusion to an extent that would negatively impact the newborn.</p><p>Crosses the placenta but to a very low extent.</p><p>Associated with a lower incidence of fetal acidosis compared to ephedrine.</p></td></tr><tr><th>Breast feed</th><td><p>Phenylephrine may potentially reduce milk production</p><p>Nasal sprays or ophthalmic drops are less likely to harm individuals who are breastfeeding.</p></td></tr><tr><th>pH</th><td><p>3.0 to 5.0</p></td></tr><tr><th>Drug-to-drug incompatibilities</th><td><p><b>Monoamine oxidase inhibitors (MAOI):</b> Taking phenylephrine within 14 days of an MAOI can cause a hypertensive crisis.</p></td></tr><tr><th>Drugs that enhance the pressor effects of Phenylephrine</th><td><p>Monoamine oxidase inhibitors (MAOI), such as selegiline.</p><p>β-adrenergic blockers</p><p>α-2 adrenergic agonists, such as clonidine</p><p>Steroids</p><p>Tricyclic antidepressants</p><p>Norepinephrine transport inhibitors, such as atomoxetine</p><p>Oxytocic drugs-Ergot alkaloids (methylergonovine, Pitocin)</p><p>Centrally acting sympatholytic agents, such as guanfacine or reserpine</p><p>Atropine sulfate</p></td></tr><tr><th>Antagonists</th><td><p>α-adrenergic blocking agents, including phenothiazines (e.g., chlorpromazine) and amiodarone, block</p><p>phenylephrine and are in turn blocked by phenylephrine.</p></td></tr><tr><th>Chemical incompatibilities</th><td><p>Acids, acid chlorides, and acid anhydrides</p><p>Oxidizing agents</p><p>Alkalis</p><p>Butacaine</p><p>Ferric salts</p></td></tr><tr><th>Contraindications</th><td><p>Hypersensitivity</p></td></tr><tr><th class="text-red">Avoid with:</th><td><p>Bradycardia</p><p>Severe cardiac dysfunction (low EF)</p><p>Hypovolemia.</p><p>PHT</p><p class="text-bold">It may worsen the following:</p><p>Heart failure</p><p>Pulmonary hypertension</p><p>Severe arteriosclerosis</p><p class="mb-20px">History of angina</p><p>The extravasation can lead to tissue necrosis or sloughing.</p></td></tr><tr><th>Antidote for toxicity</th><td><p>Phentolamine</p></td></tr><tr><th>Vol of distribution</th><td><p>340 L, it surpasses the body's total volume by a factor of 5, suggesting a high distribution into certain organ compartments.</p></td></tr><tr><th>Storage</th><td><p>At room temperature</p></td></tr></tbody></table>

Phenylephrine's effect on cardiac output (CO) depends on preload dependency.

In preload-dependent patients, phenylephrine ↑ CO:

In preload-dependent patients, they are volume-depleted or have low blood volume.

Phenylephrine can increase CO by increasing venous return and preload, especially during anesthesia-induced hypotension.

In preload-independent patients, phenylephrine ↓ CO:

In preload-independent patients, they adequate blood volume and good cardiac function.

Phenylephrine typically decreases CO by increasing afterload.

Effects of adrenergic agonists on organ systems

↑/↓: variable

| Drug | HR | MAP | CO | PVR | Bronchodilation | 
Renal

Blood Flow

 |
| --- | --- | --- | --- | --- | --- | --- |
| Phenylephrine | ↓ | ↑↑↑ | ↓or↑ | ↑↑↑ | 0 | ↓↓↓ |
| Ephedrine | ↑↑ | ↑↑ | ↑↑ | ↑ | ↑↑ | ↓↓ |
| Norepinephrine | ↓ | ↑↑↑ | ↑/↓ | ↑↑↑ | 0 | ↓↓↓ |
| Epinephrine | ↑↑ | ↑ | ↑↑ | ↑/↓ | ↑↑ | ↓↓ |
| Dobutamine | ↑ | ↑ | ↑↑↑ | ↓ | 0 | ↑ |
| Dopamine | ↑/↑↑ | ↑ | ↑↑↑ | ↑ | 0 | ↑↑↑ |
| Isuprel | ↑↑↑ | ↓ | ↑↑↑ | ↓↓ | ↑↑↑ | ↑/↓ |
| Fenoldopam | ↑↑ | ↓↓↓ | ↑/↓ | ↓↓ | 0 | ↑↑↑ |

Morgan & Mikail’s Clinical Anesthesiology 7th Ed., 2022, p. 241 (↑/↓, variable)

Receptor selectivity

| Drug | A1 | A2 | B1 | B2 | DA1 | DA2 |
| --- | --- | --- | --- | --- | --- | --- |
| Phenylephrine | +++ | + | 0 | 0 | 0 | 0 |
| Ephedrine | +++ | ? | ++ | + | 0 | 0 |
| Norepinephrine | ++ | ++ | ++ | 0 | 0 | 0 |
| Epinephrine | ++ | ++ | +++ | ++ | 0 | 0 |
| Dobutamine | 0 | 0 | +++ | + | 0 | 0 |
| Dopamine | ++ | ++ | ++ | + | +++ | +++ |
| Fenoldopam | 0 | 0 | 0 | 0 | +++ | 0 |

Morgan & Mikail’s Clinical Anesthesiology 7th Ed., 2022, p. 240

Phenylephrine

FDA Access Data (accessed 09/2025)

https://www.accessdata.fda.gov/drugsatfda\_docs/label/2023/203826Orig1s015,017lbl.pdf

Phenylephrine

DrugBank (accessed 09/2025)

https://go.drugbank.com/drugs/DB00388

Morgan & Mikhail’s Clinical Anesthesiology 7th Ed., 2022

CH.14, Adrenergic Agonists & Antagonists, p.241-242

Stoelting's Pharmacology and Physiology in Anesthesia Practice 6th ed. 2022

CH. 18, Sympathomimetic Drugs p. 459-460

Pamela Flood and James P. Rathmell